ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Effective"

  • Abstract Number: 1302 • 2019 ACR/ARP Annual Meeting

    Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study

    Marc C. Hochberg1, John Carrino 2, Thomas Schnitzer 3, Ali Guermazi 4, Eric Vignon 5, David Walsh 6, Alexander White 7, Satoru Nakajo 8, Robert Fountaine 9, Anne Hickman 9, Glenn Pixton 10, Lars Viktrup 11, Mark T. Brown 9, Christine R. West 9 and Kenneth M. Verburg 9, 1University of Maryland School of Medicine, Baltimore, MD, 2Hospital for Special Surgery, New York, NY, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Boston Medical Center, Boston, 5Université Claude Bernard Lyon 1, Lyon, France, 6Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, 7Progressive Medical Research, Port Orange, FL, 8Nakajo Orthopaedic Clinic, Miyagi, Japan, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, Morrisville, NC, 11Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Tanezumab is a monoclonal antibody that inhibits nerve growth factor and is under investigation for chronic pain treatment. Tanezumab administered intravenously was effective and…
  • Abstract Number: 1657 • 2018 ACR/ARHP Annual Meeting

    The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis

    Philip Helliwell1, Alice B Gottlieb2, Atul A. Deodhar3, Wolf-Henning Boehncke4, Dennis McGonagle1, Xie L. Xu5, Stephen Xu5, Yuhua Wang5, Elizabeth C Hsia5,6, Chetan S Karyekar5 and Philip J. Mease7, 1U of Leeds, Leeds, United Kingdom, 2NY Medical College, Metropolitan Hospital, NY, NY, 3Oregon Health & Science U, Portland, OR, 4U of Geneva, Geneva, Switzerland, 5Janssen Research & Development, LLC, Spring House, PA, 6U Penn School of Medicine, Phila, PA, 7Swedish Medical Center & U of Wash, Seattle, WA

    Background/Purpose: In a Phase 2 study, Guselkumab (GUS) was shown to be safe & effective in pts w/active PsA w/meaningful improvements in enthesitis. To evaluate…
  • Abstract Number: 1756 • 2018 ACR/ARHP Annual Meeting

    Systematic Review of the Clinical Effectiveness of Treatments in Eosinophilic Granulomatosis with Polyangiitis

    Scott Doyle1, Annete Njue2, Matthew Lyall2, Rebecca Rushton2, Anne Heyes2 and Maebh Kelly3, 1Value Evidence and Outcomes, GlaxoSmithKline, London, United Kingdom, 2RTI Health Solutions, Manchester, United Kingdom, 3Pope Woodhead, London, United Kingdom

    Background/Purpose: To better understand the available clinical effectiveness data in eosinophilic granulomatosis with polyangiitis (EGPA), a systematic literature review was undertaken. The primary objective of…
  • Abstract Number: 1786 • 2018 ACR/ARHP Annual Meeting

    Favourable Response to Rituximab for the Treatment of IgG4-Related Disease: Long-Term Follow-up of 10 Patients Resistant to Glucocorticoids and Immunosuppressives

    Emin Oguz1, Gizem Dagcı2, Murat Erdugan1, Bahar Artim-Esen1, Ahmet Gül1, Lale Ocal1 and Murat Inanc3, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Istanbul Unıversity, Istanbul Faculty of Medicine, Istanbul, Turkey, 3Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey

    Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is a systemic, immuno-mediated fibro-inflammatory disease that affects various organ systems, with typical pathological findings and increased IgG4 levels. Glucocorticoids…
  • Abstract Number: 2187 • 2018 ACR/ARHP Annual Meeting

    Specialist Link Telephone Advice Cost Effectively Enhances Rheumatology Patient Care in Alberta, Canada

    Yolanda Martens-Vanhilst1, Dianne P. Mosher2, Linda Slocombe1 and Paul MacMullan3, 1University of Calgary, Calgary, AB, Canada, 2Med, University of Calgary, Calgary, AB, Canada, 3Medicine, Division of Rheumatology, University of Calgary, Calgary, AB, Canada

    Background/Purpose: The Calgary zone of Alberta Health Services serves a population of almost 2million Canadians over a wide geographical area and is underserved in terms…
  • Abstract Number: 2513 • 2018 ACR/ARHP Annual Meeting

    Change in Disease Activity after Switching Etanercept (originator) to Biosimilar (Benepali) Is Associated with Active Disease at Baseline

    Kaushik Rajamani1 and Ernest Choy2,3,4,5,6,7, 1Adult Rheumatology, University Hospital of Wales, Cardiff, United Kingdom, 2Section of Rheumatology, Cardiff University, Cardiff, Great Britain, 3Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, 4CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, 5CREATE Center, Cardiff University School of Medicine, Cardiff, Great Britain, 6Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, 7CREATE Center, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose: Biosimilar contains a version of active substance similar of an already approved biological agent in terms of quality, characteristic, biological activity, safety and efficacy.…
  • Abstract Number: 2624 • 2018 ACR/ARHP Annual Meeting

    Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis

    Dongze Wu1, Tingting Xu2, Isaac T. Cheng1, Steven H.M. Lam1, Jiang Yue1, Priscilla Wong1, Edmund Li1, Tena K. Li1 and Lai-Shan Tam3, 1Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, 2China Center for Health Development Studies, Peking University, Beijing, China; Department of Health Policy and Administration, Peking University School of Public Health, Beijing, China, Beijing, China, 3Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong

    Background/Purpose: For patients with psoriatic arthritis (PsA) failing the first TNF-inhibitor, switching to biologic DMARDs [bDMARDs] with different mechanism of actions (swapping strategy) may be…
  • Abstract Number: 2650 • 2018 ACR/ARHP Annual Meeting

    Efficacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus

    Luca Iaccarino1, Francesca Saccon1, Alessandro Mathieu2, Matteo Piga3, Angela Ceribelli4, Carlo Selmi5, Paolo Cardinaletti6, Armando Gabrielli7, Andrea Di Matteo8, Rossella De Angelis9, Paola Faggioli10, Antonella Laria11, Micaela Fredi12, Francesca Regola13, Angela Tincani12, Laura Andreoli14, Giulia Pazzola15, Carlo Salvarani15, Francesco Puppo16, Ottavia Magnani16, Marcella Prete17, Elisa Gremese18, Maria Gerosa19, Tania Ubiali20, Enrica Bozzolo21, Valentina Canti21, Vito Racanelli17, Fabrizio Conti22, Fulvia Ceccarelli23, Elena Bartoloni24, Roberto Gerli25, Antonio Lobasso26, Amato de Paulis27, Ginevra De Marchi28, Salvatore De Vita29, Alessandra Bortoluzzi30, Marcello Govoni30, Francesco Benvenuti31, Margherita Zen32, Marta Mosca33, Chiara Tani34, Maurizio Rossini35, Giovanni Orsolini35, Salvatore Scarpato36, Ernico Brunetta37, Aurora Zumbo38, Giacomo Tanti39 and Andrea Doria40, 1Department of Medicine-DIMED, University of Padova, Padova, Italy, 2University of Cagliari, Cagliari, Italy, 3Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, 4Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, 5Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, 6University of Ancona, Ancona, Italy, 7Univeristy of Ancona, Ancona, Italy, 8Polytechnic University of Marche, Rheumatology Clinic, Jesi, Italy, 9Polytechnic University of Marche, Rheumatology Clinic, jesi, Italy, 10Hospital of Legnano, Legnano, Italy, 11Hospital of Magenta, Magenta, Italy, 12Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 13University of Brescia, Brescia, Italy, 14Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 15University of Reggio Emilia, Reggio Emilia, Italy, 16University of Genova, Genova, Italy, 17University of Bari, Bari, Italy, 18Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, 19Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, 20Istituto Gaetano Pini, University of Milano, Milano, Italy, 21Hospital San Raffaele, Milano, Italy, 22Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, 23UO Complessa Reumatologia, Policlinico Umberto I Università Sapienza di Roma, Rome, Italy, 24Rheumatology Unit, University of Perugia, Perugia, Italy, 25Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, 26University Federico II of Napoli, Napoli, Italy, 27Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy, 28Hospital/University of Udine, Udine, Italy, 29Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, 30UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, 31University of Padova, Padova, Italy, 32Division of Rheumatology, University of Padova, Padova, Italy, 33Rheumatology Unit, University of Pisa, Pisa, Italy, 34Univeristy of Pisa, Pisa, Italy, 35Rheumatology Unit, University of Verona, Verona, Italy, 36Hospital of Salerno, Salerno, Italy, 37Humanitas Hospital, Milano, Italy, 38Humnaitas Hospital, Milano, Italy, 39Catholic University of the sacred hearth, Roma, Italy, 40University and Azienda Ospedaliera of Padova, Padova, Italy

    Background/Purpose: To investigate effectiveness, safety, and predictors of response to belimumab in patients with active SLE in clinical practice setting. Methods: Four hundred and one…
  • Abstract Number: 256 • 2018 ACR/ARHP Annual Meeting

    The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences

    Robert S. Katz, Rush University Medical Center, Chicago, IL

    Background/Purpose: We asked patients with fibromyalgia to rank the effectiveness of medications they have tried. Methods: In a rheumatology office practice, 95 patients (mean age…
  • Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting

    Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE

    Anne C. Bay-Jensen1, Christian S. Thudium1, Claus Christiansen2 and Morten A. Karsdal1, 1Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Clinical Development, Herlev, Denmark

    Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…
  • Abstract Number: 633 • 2018 ACR/ARHP Annual Meeting

    The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis

    Dafna D Gladman1, Wolf-Henning Boehncke2, Alice B Gottlieb3, Philip Helliwell4, Peter Nash5, Xie L. Xu6, Stephen Xu6, Yuhua Wang6, Elizabeth C Hsia6,7, Chetan S Karyekar6 and Atul A. Deodhar8, 1Krembil Research Institute, U of Toronto, Toronto, ON, Canada, 2U of Geneva, Geneva, Switzerland, 3NY Medical College, Metropolitan Hospital, NY, NY, 4U of Leeds, Leeds, United Kingdom, 5U of Queensland, Brisbane, Australia, 6Janssen Research & Development, LLC, Spring House, PA, 7U Penn School of Medicine, Phila, PA, 8Oregon Health & Science University, Portland, OR

    Background/Purpose: In a Ph2 study, GUS was shown to be safe&effective in pts w/active PsA. We evaluated effect of GUS on dactylitis in subset of…
  • Abstract Number: 1261 • 2018 ACR/ARHP Annual Meeting

    Development a Core Domain Set to Assess Shared Decision Making Interventions in Rheumatology: An OMERACT White Paper to Facilitate Endorsement

    Karine Toupin-April1, Jennifer Barton2,3, Liana Fraenkel4, Alexa Meara5, Linda Li6, Peter Brooks7, Maarten de Wit8, Dawn Stacey9,10, France Légaré11, Beverly Shea9,12,13, Anne Lyddiatt14, Catherine Hofstetter15, Robin Christensen16, Marieke Scholte-Voshaar17,18, Maria Suarez-Almazor19, Annelies Boonen20, Tanya Meade21,22, Lyn March22, Janet Elizabeth Jull9, Willemina Campbell23, Rieke Alten24, Suvi Karuranga25, Esi Morgan26, Jessica Kaufmann27, Sophie Hill27, Lara J. Maxwell9,10, Dorcas Beaton28, Yasser El-Miedany29, Shikha Mittoo30, Susan J. Bartlett31, Jasvinder A. Singh32 and Peter Tugwell33, 1Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, 2VA Portland Health Care System, Portland, OR, 3Oregon Health & Science University, Portland, OR, 4Yale University School of Medicine, New Haven, CT, 5Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 6Arthritis Research Canada, Richmond, BC, Canada, 7The University of Melbourne, Victoria, Australia, 8EULAR standing committee of PARE, Zurich, Switzerland, 9University of Ottawa, Ottawa, ON, Canada, 10The Ottawa Hospital Research Institute, Ottawa, ON, Canada, 11Université Laval, Montreal, QC, Canada, 12Bruyere Research Institute, Ottawa, ON, Canada, 13School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada, 14Musculoskeletal Group, Cochrane Collaboration, Hamilton, ON, Canada, 15OMERACT patient research partner group, Ottawa, ON, Canada, 16Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, 17University of Twente, Enschede, ON, Netherlands, 18OMERACT patient research partner group, Enschede, Netherlands, 19Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 20Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands, Maastricht, Netherlands, 21Western Sydney University, New South Wales, Australia, 22University of Sydney, New South Wales, Australia, 23OMERACT patient research partner group, Toronto, ON, Canada, 24University Medicine Berlin, Berlin, Germany, 25Access to Medicine Foundation, Haarlem, Netherlands, 26University of Cincinnati, Cincinnati, OH, 27La Trobe University, Victoria, Australia, 28Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada, 29Ain Shams University, Cairo, Egypt, 30Involved medicine, Toronto, ON, Canada, 31Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 32Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 33Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada

    Background/Purpose: Shared decision making (SDM) improves decisional outcomes and patient-physician communication and holds great potential for improving the management of various rheumatology conditions. However, the…
  • Abstract Number: 1546 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of Corticosteroids in Rheumatoid Arthritis: Systematic Literature Review and Practical Recommendations

    Raimon Sanmartí1, Jesús Tornero Molina2, Francisco Javier Narváez3, Alejandro Muñoz4, Elena Garmendia5, Ana M. Ortiz Garcia6, Miguel A. Abad7, Patricia Moya8, Maria Lourdes Mateo9, Delia Reina10, Juan Salvatierra Osorio11, Sergio Rodriguez12, Ana Rubial Escribano13, Natalia Palmou-Fontana14 and Jaime Calvo-Alén15, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Rheumatology Unit, Hospital de Guadalajara, Guadalajara, Spain, 3Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, 4Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 5Rheumatology, Hospital Universitario Cruces. Barakaldo. Spain, Barakaldo, Spain, 6Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, 7FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, 8Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 9Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 10Rheumatology, Hospital Moises Broggi, Sant Joan Despí, Spain, 11Complejo Hospitalario Universitario de Granada, Granada, Spain, 12Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, 13Rheumatology, Hospital Alfredo Espinosa, Urduliz, Spain, 14Hospital Universitario Marqués de Valdecilla, IDIVAL. Universidad of Cantabria, Santander, Spain, 15Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain

    Background/Purpose: Corticosteroids are effective in rheumatoid arthritis (RA) patients but their adverse events limit their use. The aim of this study was to: 1) To…
  • Abstract Number: 1552 • 2018 ACR/ARHP Annual Meeting

    No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials

    Mary Safy1, Johannes W. G. Jacobs1, Michael Edwardes2, Maria JH de Hair1, Xavier M Teitsma1, Paco MJ Welsing1, Michelle EA Borm3, Yves Luder4, Jacob van Laar1, Attila Pethö-Schramm4 and Johannes W. J. Bijlsma5, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, 2Everest Clinical Research, Markham, ON, Canada, 3Roche Nederland BV, Woerden, Netherlands, 4F. Hoffmann-La Roche, Basel, Switzerland, 5Rheumatology & Clinical Immunology department University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

    No effect of concomitant glucocorticoid therapy on efficacy and safety of tocilizumab monotherapy in rheumatoid arthritis clinical trialsM. Safy1, J.W.G. Jacobs1, M. Edwardes2, M.J.H. de…
  • Abstract Number: 449 • 2017 ACR/ARHP Annual Meeting

    Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review

    Rongqiang Zhang1, Puwei Yuan2, Jia Li3, Bo Dong1, Wulin Kang3, Stephanie Hyon4, Raveendhara R. Bannuru5, William F. Harvey4 and Chenchen Wang4, 1Shaanxi University of Chinese Medicine, Xianyang 712046, China, Xianyang, China, 2Shaanxi University of Chinese Medicine, Xianyang 712046, China, XianYang, China, 3Shaanxi University of Chinese Medicine, Xianyang, China, 4Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, 5Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA

    Background/Purpose: Medical bugs, a term used to describe insects and arthropods for medical treatment, have been widely used in the past centuries for pain relief.…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology